Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vir Biotechnology, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at up to $300.0 million (effective 2023-11-03).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Cowen and Company, LLC
- Value
- up to $300.0 million
- Effective
- 2023-11-03
Exact text from the filing
On November 3, 2023, Vir Biotechnology, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC, as sales agent (“TD Cowen”), pursuant to which the Company may from time to time offer and sell shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), having an aggregate offering price of up to $300.0 million, through or to TD Cowen, acting as sales agent or principal.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vir Biotechnology, Inc. terminated Prior Sales Agreement with TD Cowen (effective 2023-11-03).
- Action
- termination
- Agreement
- atm program
- Counterparty
- TD Cowen
- Effective
- 2023-11-03
Exact text from the filing
On November 3, 2023, and in connection with entering into the Sales Agreement, the Company and TD Cowen agreed to terminate, effective as of immediately prior to the entry by the parties into the Sales Agreement, the sales agreement that the Company previously entered into with TD Cowen on November 10, 2020 (the “Prior Sales Agreement”).
View on SEC.gov